Market news

The insider sold 1,650 shares but still retains nearly 8,000 shares.

GLOUCESTER, England, September 03, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City:

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we’ll examine how the raised 2026 growth...

LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a year to date share price return of 33.21%. The 1 year total...

Motley Fool Press Release.

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

Moby summary of LivaNova PLC's Q2 2026 earnings call

LivaNova PLC (LIVN) delivers 9.8% constant currency revenue growth, raises full-year outlook, and secures key oxygenator supply agreement.

While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LivaNova (NASDAQ:LIVN) reported second-quarter results that surpassed Wall Street expectations, prompting the medical technology company to raise its earnings and revenue guidance for the full year. The stronger performance helped lift the shares around 1.

LivaNova (LIVN) delivered earnings and revenue surprises of +16.67% and +2.90%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LivaNova PLC (LIVN) reported Q2 adjusted earnings Wednesday of $1.26 per diluted share, up from $1.0

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

GLOUCESTER, England, August 05, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance.

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.